A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

Michael Friedlander, Tarek Meniawy, Ben Markman, Linda R. Mileshkin, Paul Harnett, Michael Millward, J. Lundy, A. E. Freimund, C. Norris, S Mu, V Paton, L Wang, Bo Gao

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Number of pages2
JournalJournal of Clinical Oncology
Volume36
Issue number5
DOIs
Publication statusPublished - 10 Feb 2018
EventASCO-SITC Clinical Immuno-Oncology Symposium - San Francisco, Canada
Duration: 25 Jan 201827 Jan 2018

Cite this